Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec, in Children and Adolescents With Type 1 Diabetes: The onset 7 Trial | Zendy

Bruce W. Bode | Zendy; Violeta Iotova | Zendy; М. А. Коваренко | Zendy; Lori M. Laffel | Zendy; Paturi Vishnupriya Rao | Zendy; Srikanth Deenadayalan | Zendy; Magnus Ekelund | Zendy; Steffen Falgreen Larsen | Zendy; Thomas Danne | Zendy

Open Access

Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec, in Children and Adolescents With Type 1 Diabetes: The onset 7 Trial

Author(s) -

Bruce W. Bode,

Violeta Iotova,

М. А. Коваренко,

Lori M. Laffel,

Paturi Vishnupriya Rao,

Srikanth Deenadayalan,

Magnus Ekelund,

Steffen Falgreen Larsen,

Thomas Danne

Publication year - 2019

Publication title -

diabetes care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.636

H-Index - 363

eISSN - 1935-5548

pISSN - 0149-5992

DOI - 10.2337/dc19-0009

Subject(s) - insulin aspart , medicine , postprandial , type 2 diabetes , discontinuation , glycated hemoglobin , insulin detemir , insulin degludec , endocrinology , type 1 diabetes , clinical endpoint , hypoglycemia , insulin , population , diabetes mellitus , randomized controlled trial , insulin glargine , environmental health

To confirm efficacy and safety of fast-acting insulin aspart (faster aspart) versus insulin aspart (IAsp), both with basal insulin degludec, in a pediatric population with type 1 diabetes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research